Can an immune booster stop serious infections in blood cancer patients?
NCT ID NCT07582432
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding Gamunex-C (an immune globulin) to standard care can prevent serious infections in people with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma. About 49 participants will receive Gamunex-C through an IV every 4 weeks for a year. The main goal is to see if the rate of serious bacterial infections drops.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gamunex-C (immune globulin injection)
- What this could lead to
- If it works, this could provide a way to reduce serious infections in people with blood cancers who have weakened immune systems.
- What could go wrong
- This is a small, single-arm trial with no placebo group, so results may be less reliable. Side effects from Gamunex-C can include headache, fever, and allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA, MULTIPLE MYELOMA, OR NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Study Site 101
RECRUITINGFort Wayne, Indiana, 46894, United States
-
Study Site 102
NOT_YET_RECRUITINGSt. Petersburg, Florida, 33709, United States
-
Study Site 103
NOT_YET_RECRUITINGTacoma, Washington, 98405, United States
-
Study Site 104
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
-
Study Site 105
NOT_YET_RECRUITINGWestbrook, Maine, 04092, United States